CNS Pharmaceuticals, Inc. (CNSP)
$2.12
-0.06 (-2.75%)
Rating:
Recommendation:
-
| Symbol | CNSP |
|---|---|
| Price | $2.12 |
| Beta | 1.132 |
| Volume Avg. | 0.07M |
| Market Cap | 11.127M |
| Shares () | - |
| 52 Week Range | 0.611-4.4 |
| 1y Target Est | - |
| DCF Unlevered | CNSP DCF -> | |
|---|---|---|
| DCF Levered | CNSP LDCF -> | |
| ROE | -615.75% | Strong Sell |
| ROA | -815.85% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -2.41% | Neutral |
| P/E | -0.28 | Neutral |
| P/B | -5.09 | Strong Sell |
Latest CNSP news
About
Download (Excel)Mr. John Michael Climaco Esq., J.D.
Healthcare
Biotechnology
NASDAQ Capital Market
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.